Overview

A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
0
Participant gender:
All
Summary
Purpose of this phase I/II study is to test how well LY2090314 works in combination with different chemotherapies in treating participants with metastatic pancreatic cancer.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Mayo Clinic
Treatments:
Albumin-Bound Paclitaxel
Fluorouracil
Gemcitabine
Leucovorin
Oxaliplatin
Paclitaxel
Criteria
Inclusion Criteria:

- Metastatic pancreatic cancer with metastases amenable to biopsy

- Willingness to provide tissue and blood samples for research purposes

- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1

Exclusion Criteria:

- History of islet cell, acinar cell, or cystadenocarcinomas

- Prior cytotoxic chemotherapy for metastatic disease, except prior gemcitabine or
FOLFIRINOX (5FU + leucovorin + irinotecan + oxaliplatin)

- Radiation therapy, immunotherapy or biologic therapy <28 days prior to study entry